Duration: May, 2021 to May, 2023
Researcher: Felipe Murta
Funding: Medicines for Malaria Venture
Tafenoquine is a drug used to prevent and treat malaria, a disease caused by a parasite that is transmitted to humans through the bite of infected mosquitoes. In Brazil, malaria is a significant public health issue, particularly in the Amazon region where the disease is highly endemic. Tafenoquine is a new drug that has been approved by the Brazilian Health Regulatory Agency (ANVISA) for use in the treatment of malaria, and it is now being used in Brazil to combat this disease.
STUDY GOALS
To understand the factors that impact on the level of adherence to the use of new tools for treatment and elimination of P. vivax malaria at different levels of the health services, including the community level in Brazil.
Study Sites: Urban, peri-urban and rural areas of Manaus and Porto Velho, Brazil.
The study population includes healthcare professionals, such as doctors, community health agents, microscopists, and endemic agents from various types of healthcare facilities (including higher, medium, and basic level facilities), as well as patients diagnosed with P. vivax malaria.
